SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Reports that Papa Johns largest U.S. franchisee has joined Irth Capitals take-private bid have revived buyout speculation. Traders are hopeful but divided over whether a deal will close, with frustration at the boards silence and continued concerns about weak sales and the suspended dividend.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp XCN price spike is driving attention, with traders highlighting a large candle and rapid gains despite no clear new catalyst. The community is split between buyers anticipating a breakout and skeptics calling the move another short-lived pump-and-dump, while some attribute price swings to Bitcoin and broader crypto-market conditions.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Crudes rally amid escalating Middle East tensions and supply-disruption fears is driving attention to UCO, with traders focused on shipping risks and tight oil markets. Many are bullish on oil exposure, while others warn of a sharp run-up and possible pullback; the Russian diesel supply deal also raises debate about whether added supply could ease prices.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens IMDELLTRAIMFINZI combination showed a substantial survival benefit in a Phase 3 trial for first-line extensive-stage small-cell lung cancer, drawing attention to the drugs potential expansion and growth prospects. Traders are broadly positive on the data, while some debate how much it could add commercially alongside established products such as Repatha.

TOSHI

TOSHI is drawing attention around increased trading activity and repeated attempts to break a stubborn resistance level, with traders speculating about a breakout or short squeeze. Bulls are buying dips and expecting a rebound, while skeptics point to repeated rejections, weak price action, and broader crypto-market softness.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on Dow and broader-market volatility, with traders weighing rallies and the Dows relative strength against concerns about rising Treasury yields, inflation and Fed policy, and Iran-related oil risks. Views are split between bullish calls for continued gains and warnings of further declines; no single company-specific catalyst dominates.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

SHIBs extended sideways trading and repeated consolidation near recent levels dominate the conversation, with traders sharing technical levels and debating whether to buy dips or expect another meme-coin rally. Optimistic holders are accumulating and waiting for a breakout, while others are frustrated by the lack of momentum and question the tokens utility and prospects.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

New ESMO subgroup analyses from the Phase 3 VIKTORIA-1 breast cancer study, showing strong efficacy for gedatolisib, are driving discussion. Traders are impressed by the results but note they are additional analyses rather than new topline data, and debate whether clinical progress can translate into commercial uptake and revenue.

Anthropic

Anthropics reported preparations for a potential mega-IPO are driving attention, with traders focused on the timing, filing and possible valuation. The community is divided between enthusiasm for rapid revenue growth and skepticism about the companys heavy infrastructure commitments, losses and intensifying AI competition.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

Voyagers proposed convertible-notes financing has fueled concerns about dilution and added pressure to a stock many traders say has lagged other space names. The community is split between frustrated holders blaming management and financing decisions, and buyers who see the pullback as an opportunity based on the companys longer-term space and defense prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors

In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.

ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.

Here's Why Adma Biologics (ADMA) Fell More Than Broader Market

In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.

Why Adma Biologics (ADMA) Dipped More Than Broader Market Today

Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know

Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Tumbles On Slashed Outlook As Short-Seller Aftermath Meets Competitive Headwinds  

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Earlier this year, Culper Research alleged channel stuffing and undisclosed related-party transactions at Adma.&nbsp;</li><li>Adma said on Wednesday that there is no evidence of any illegal activity at the company.&nbsp;</li><li>The firm also withdrew its previously issued long-term guidance.</li></ul>ADMA Biologics (ADMA) shares plunged 24% in after-hours trading on Wednesday following the release of disappointing first-quarter results that showed flat revenue and a sharp cut to full-year guidance amid intensifying competition in the U.S. immunoglobulin (IG) market.ADMA reported first-quarter 2026 total revenue of $114.5 million, essentially flat compared with $114.8 million in the year-ago period and well below Wall Street expectations of roughly $140 million.The top-line miss was driven by a steep decline in BIVIGAM sales, which fell 54% year-over-year to $15.4 million, while ASCENIV sales grew 28% to $97.5 million. Both ASCENIV and BIVIGAM are used to treat primary humoral immunodeficiency, a group of inherited disorders leading to low antibody production.Despite the revenue stall, profitability metrics improved markedly. Diluted earnings per share came in at $0.19, above the $0.11 reported in the corresponding quarter of 2025, and in line with Wall Street expectations.<h2 class="st-heading-2">Management Weighs In On Competition</h2>In a statement, President and CEO Adam Grossman acknowledged near-term challenges but emphasized underlying strength in ASCENIV demand.“During the first quarter, the market for U.S. plasma-derived therapies and immunoglobulin experienced increased competitive dynamics which, along with variability in distributor ordering patterns, created near-term topline pressures, particularly impacting BIVIGAM,” Grossman said.“Importantly, these dynamics were limited to distribution and inventory behavior and we believe do not reflect any deterioration in underlying ASCENIV demand, where fundamentals remained strong and continue to improve—with record utilization growth throughout the quarter.”Grossman described Q1 results as a likely “trough revenue baseline” caused by what the company views as a “temporary market dislocation.”<h2 class="st-heading-2">ADMA’s 2026 Guidance</h2>ADMA updated its 2026 financial outlook to reflect the evolving competitive landscape. The company now expects full-year revenue of $530 million to $560 million, down from prior guidance above $635 million, and adjusted core profit of $265 million to $300 million. It also withdrew its previously issued long-term guidance.The company attributed the softer outlook to sustained pricing pressure on standard IG products and changing competitive dynamics.<h2 class="st-heading-2">Short-Seller Report</h2>ADMA also addressed lingering investor concerns stemming from a Culper Research report earlier this year that <a href="https://stocktwits.com/news-articles/markets/equity/adma-stock-drops-after-culper-research-alleges-channel-stuffing/cZ3nq7uRI1i">alleged</a> channel stuffing and undisclosed related-party transactions. Culper alleged in a report that Adma’s reported growth is a “fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor." Without the sales figure inflation, Culper estimated Adma's revenues declined 3% in 2025 as compared to the 20% growth reported.However, Adma said on Wednesday that its Audit Committee, assisted by independent forensic accountants and external counsel, completed a review and “concluded that ADMA has not engaged in any improper channel stuffing or any undisclosed related party transactions,” finding “no evidence of any illegal activity,” it said.<h2 class="st-heading-2">How Did ADMA Retail Traders React?</h2>On Stocktwits, retail sentiment around ADMA stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that investors who invest now at ‘peak negativity’ stand the chance to make a lot of money.<stembedurl>https://www.stocktwits.com/david999957/message/652525861</stembedurl>Another opined that it is just a “terrible luck” year for the company with the short seller report and market dislocation for Bivigam.<stembedurl>https://www.stocktwits.com/azv134/message/652522379</stembedurl><a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> has fallen 56% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/srpt-stock-plunges-after-hours-as-elevidys-demand-slumps-ceo-still-sees-return-to-growth/cZQzkcWReOx">SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

In a statement, President and CEO Adam Grossman acknowledged near-term challenges but emphasized underlying strength in its therapy ASCENIV’s demand.

iShares Core S&P Small-Cap ETF

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$10.68
Prev Close	$10.95
Open	$10.88
Dividend Yield	0.00%
50-Day Moving Average	$9.83
Beta	1.19
Avg. Volume	3M
PE Ratio	15.16

52-Week High	$20.46
52-Week Low	$7.21
Market Capitalization	$2.39B
EPS (Annual)	$0.60
Price to Book	5.90
Revenue Per Employee	$788,520.87

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADMA Fundamentals